USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO should be discontinued as soon as possible. See
WARNINGS: Fetal/Neonatal Morbidity and Mortality.
|
|
AVAPRO SUMMARY
AVAPRO®* (irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist.
Hypertension
AVAPRO (irbesartan) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Nephropathy in Type 2 Diabetic Patients
AVAPRO is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, AVAPRO reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) (see
CLINICAL PHARMACOLOGY: Clinical Studies).
|
|
NEWS HIGHLIGHTS
Published Studies Related to Avapro (Irbesartan)
Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on
Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled
One-Year Intervention Trial (the SAFIR Study). [2015] angiotensin II receptor blocker (ARB) irbesartan... CONCLUSION: Use of the ARB irbesartan as an add-on to other antihypertensive
Visit-to-visit variability in blood pressure and kidney and cardiovascular
outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis
from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. [2014] diabetes and nephropathy... CONCLUSIONS: In diabetic individuals with nephropathy, systolic blood pressure
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. [2011.11.02] Background Cholesterol and blood pressure lowering therapies are effective in the secondary prevention of ischemic stroke. Aim To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke.Conclusions Treatment with atorvastatin and irbesartan, initiated on day 3 after acute ischemic stroke, did not appear to substantially modify infarct growth.
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. [2011.11] BACKGROUND: In vitro and animal experiments have shown inhibiting effects of angiotensin receptor blockers (ARBs) on the formation of advanced glycation end products (AGEs), which are known to be involved in the development of cardiovascular complications in diabetes. However, sufficient human data to confirm such beneficial effects of ARBs on AGEs are lacking. Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(epsilon)(1-carboxymethyl)lysine (CML) and N(epsilon)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria... CONCLUSIONS: Long-term irbesartan treatment does not influence plasma levels of the AGE CML and CEL in patients with type 2 diabetes and microalbuminuria.
Role of irbesartan in prevention of post-coronary artery bypass graft atrial fibrillation. [2011.08.01] BACKGROUND AND OBJECTIVE: Atrial fibrillation (AF) is a common complication of cardiothoracic surgery (CTS). Existing evidence about the potential protective role of angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) for post-CTS AF has been limited and conflicting. In this single-blind, open-label, randomized prospective pilot study, we evaluated the potential protective role of irbesartan (an ARB) in post-coronary artery bypass graft (CABG) AF... CONCLUSION: Pretreatment with irbesartan tends to have a significant protective effect against the occurrence of AF during the post-operative period in patients undergoing CABG.
Clinical Trials Related to Avapro (Irbesartan)
Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans [Recruiting]
The purpose of this study is to test the hypothesis that hypertension increases the
anti-natriuretic effects of an angiotensin receptor antagonist during mental stress in
overweight/obese AA's who retain sodium during mental stress.
Irbesartan and Adhesion Molecules in AF [Recruiting]
Experimental data suggest that angiotensin II-antagonists reduce the atrial expression of
prothrombotic adhesion molecules and oxidative stress parameters. The present study is
designed to investigate the effects on angiotensin II-antagonist irbesartan to reduce the
amounts of circulating oxidative stress markers and adhesion molecules in patients with
persistent atrial fibrillation.
A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin [Completed]
Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF) [Completed]
The main purpose of the study is to compare the mean AERP between treatment groups based on
the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological
remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to
placebo.
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension [Completed]
The purpose of this clinical research is to learn if moderate hypertension can be better
controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients
who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition,
the study will also evaluate the safety and tolerability of the drugs.
Reports of Suspected Avapro (Irbesartan) Side Effects
Loss of Consciousness (28),
Blood Pressure Increased (25),
Palpitations (23),
Dizziness (20),
Weight Decreased (18),
Blood Count Abnormal (16),
Cystitis (16),
Burning Sensation (16),
Ingrowing Nail (15),
Hyperkalaemia (14), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 2 ratings/reviews, Avapro has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| Avapro review by 58 year old male patient | | Rating |
Overall rating: | | |
Effectiveness: | | Highly Effective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | hypertension |
Dosage & duration: | | 150mg taken once daily for the period of ongoing - has been one year |
Other conditions: | | none |
Other drugs taken: | | none | | Reported Results |
Benefits: | | Since I've started the treatment, my tension has stabilized. I've monitored it quite frequently after beginning the treatment to see assess the progress. It seems to also have an impact on my ability to maintain a lower blood pressure than before during physical activities. |
Side effects: | | None that I've noticed. |
Comments: | |
My doctor has prescribed one tablet daily as an ongoing treatment. |
|
| Avapro review by 41 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Highly Effective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | high blood pressure after prewgnancy |
Dosage & duration: | | 150mg taken one a day for the period of on going |
Other conditions: | | none |
Other drugs taken: | | none | | Reported Results |
Benefits: | | after being given this treatment there was no coughing no vomitinig like i had experienced with some other bp medication |
Side effects: | | there were no side effects |
Comments: | | had blood pressure at 7 month pregnant was taking labetolol after pregnancy tred a few which made me feel ill aprovel makes me feel very well no side effect my blood pressure is now the lowest it has ever been even before i was pregnant |
|
|
Page last updated: 2015-08-10
|